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Figure S1. Expression of Fgfr2 in a wave 2 derived inside cell positioned at the 
surface of the ICM. Detail of the adjacent TE cell shows that Fgfr2 expression 
detected in the wave 2 inside cell is not associated with trophectodermal processes 
belonging to the adjacent TE cell. 
 
Figure S2. (A) Overexpression in half of the embryo by injection of mRNA to one 
blastomere at the 2-cell stage. (B) Confirmation of Fgfr2 overexpression at the 8-cell 
stage. Injected cells are marked by GFP expression.  
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Figure legend
(A) 16-cell-stage embryos. Left panels: FISH of Fgfr2 mRNA. Right panels: 
Immunostaining of FGFR2 protein. Both Fgfr2 mRNA and FGFR2 protein are expressed 
at higher levels in outside cells in the 16-cell-stage embryo. (B) Fgfr2 inhibition with
the small molecule inhibitor, PD173074. Left panel: Immunostaining of Sox17 in control,
untreated embryo showing defined PE layer. Right panel: Absence of Sox17 positive 
cells in PD173074 treated embryo, see also graphical representation below. (C) Fgfr2
overexpression (upper panels). Graph below demonstates Fgfr2 overexpressing cells
are driven to PE fate (p<0.001). (D) Cell fate of Fgfr2 injected clone upon receptor
inhibition with PD173074 - cells do not acquire PE fate as demonstrated by absence of
Sox17-positive cells. (E) Confirmation of FGFR2 overexpression.
E 
GFP  Fgfr2  DAPI            Fgfr2  DAPI 
A
B
Supplementary Figure 2 
Supplementary Figure 2. (A) Over-expression of mRNA in half of the embryo by injection into one 
blastomere at the 2-cell stage. (B) Confirmation of Fgfr2 over-expression at the 8-cell stage, injected 
cells are marked by GFP expression. Scale bar indicates 10µm.!
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Supplementary Figure 1. Expression of FGFR2 in a wave 2 derived inside cell positioned at the 
surface of the ICM. Detail of the adjacent TE cell shows that FGFR2 expression detected in the wave 
2 inside cell is not associated with trophectodermal processes belonging to the adjacent TE cell. 
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at higher levels in outside cells in the 16-cell-stage embryo. (B) Fgfr2 inhibition with
the small molecule inhibitor, PD173074. Left panel: Immunostaining of Sox17 in control,
untreated embryo showing defined PE layer. Right panel: Absence of Sox17 positive 
cells in PD173074 treated embryo, see also graphical representation below. (C) Fgfr2
overexpression (upper panels). Graph below demonstates Fgfr2 overexpressing cells
are driven to PE fate (p<0.001). (D) Cell fate of Fgfr2 injected clone upon receptor
inhibition with PD173074 - cells do not acquire PE fate as demonstrated by absence of
Sox17-positive cells. (E) Confirmation of FGFR2 overexpression.
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Supplementary Figur  2. (A) Over-expr ssion of mRNA in half of the embryo by injection into one 
blastomere at the 2-cell stage. (B) Confirmati n of Fgfr2 over-expression at the 8-cell stage, injected 
c lls are marked by GFP expression. Scale bar indicates 10µm.!
  
Figure S3. Example of a chimera made with an 8-cell blastomere placed on the inside 
of the embryo, fixed at E4.5 and immunostained for Sox17 (PE) and Nanog (EPI). 
GFP expression marks progeny of the donor cell. 
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Supplementary Figure 3. Example of a chimera made with an 8-cell blastom re placed on the inside 
of th  embryo, fixed at E4.5 and i munostained for Sox17 and Nanog. GFP marks the progeny of 
the donor cell.!
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